A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

BACKGROUND. The phase II YO28252 study (NCT01590719) examined first-line onartuzumab plus mFOLFOX6 in patients with metastatic, human epidermal growth factor receptor 2-negative adenocarcinoma of the stomach or gastroesophageal junction. MET immunohistochemistry expression as a biomarker of onartuzu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2016
Soggetti:
Gastrointestinal Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5016069/
https://ncbi.nlm.nih.gov/pubmed/27401892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0038
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi